Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This clinical trial studies personalized dose monitoring of busulfan and combination
chemotherapy in treating patients with Hodgkin or non-Hodgkin lymphoma undergoing stem cell
transplant. Giving chemotherapy before a stem cell transplant stops the growth of cancer
cells by stopping them from dividing or killing them. After treatment, stem cells are
collected from the patient's peripheral blood or bone marrow and stored. The stem cells are
then returned to the patient to replace the blood-forming cells that were destroyed by the
chemotherapy. Monitoring the dose of busulfan may help doctors deliver the most accurate dose
and reduce toxicity in patients undergoing stem cell transplant.